AFMD - Affimed N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.35
-0.35 (-7.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.70
Open4.55
Bid0.00 x 3100
Ask0.00 x 1000
Day's Range4.30 - 4.73
52 Week Range1.15 - 7.35
Volume1,603,160
Avg. Volume1,819,367
Market Cap271.397M
Beta3.46
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.27
Trade prices are not sourced from all markets
  • ACCESSWIRE9 days ago

    Immuno Oncology & Targeted Therapy Companies Set to Breakout

    HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of AFMD earnings conference call or presentation 8-Aug-18 12:30pm GMT

    Q2 2018 Affimed NV Earnings Call

  • Here's Why Affimed Stock Collapsed Today
    Motley Fool21 days ago

    Here's Why Affimed Stock Collapsed Today

    The Cinderella biopharma shot up 246% a few days ago, so things aren't so bad.

  • Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)
    Zacks21 days ago

    Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)

    Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

  • Affimed (AFMD) Soars: Stock Adds 10.8% in Session
    Zacks22 days ago

    Affimed (AFMD) Soars: Stock Adds 10.8% in Session

    Affimed (AFMD) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.

  • GlobeNewswire22 days ago

    Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

    Heidelberg, Germany, August 30, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate ...

  • Affimed (AFMD) Surges On Collaboration Contract With Roche
    Zacks23 days ago

    Affimed (AFMD) Surges On Collaboration Contract With Roche

    Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

  • Up 246%: Is This Small-Cap Biotech Stock Still a Buy?
    Motley Fool23 days ago

    Up 246%: Is This Small-Cap Biotech Stock Still a Buy?

    Affimed struck a game-changing deal with Roche yesterday, causing its shares to sky-rocket.

  • ACCESSWIRE23 days ago

    Affimed Shares Leap on News of Genentech Deal, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Affimed N.V. (AFMD), a clinical-stage biopharmaceutical company, focused on cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in a Phase 2a clinical study. The share activity came on the heels of a new development agreement with Genentech.

  • Benzinga23 days ago

    The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...

  • ACCESSWIRE24 days ago

    Biotech Stocks Take Aim At New Highs In August 2018

    CORAL GABLES, FL / ACCESSWIRE / August 28, 2018 / August has been full of excitement within the biotech sector of the market. Yesterday, the Health Care SPDR ETF (XLV) hit fresh highs during early trading as sector stocks helped lead the charge for record highs in the overall markets. The healthcare sector has been an investor favorite in times of global trade crisis.

  • Benzinga24 days ago

    Affimed Shares Soar On $5B Collaboration With Roche's Genentech

    Affimed NV (NASDAQ: AFMD ) shares are trading sharply higher Tuesday after the biopharma  announced a collaboration agreement with Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY )'s Genentech unit. ...

  • Benzinga24 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Toyota Motor Corp (ADR) (NYSE: TM ) stock was trading ...

  • Benzinga24 days ago

    The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...

  • MarketWatch24 days ago

    Affimed shares more than double after $96 million Genentech agreement

    Shares of Affimed NV (afmd) more than doubled in the extended session Monday after the Germany-based pharma company, which focuses on cancer immunotherapies, said it has entered into an agreement with Roche Holding's (ch:rog) Genentech to develop and commercialize immunotherapeutic treatments for multiple cancers. Affimed will apply a proprietary platform which enables antibodies, to "discover and advance" immunotherapeutics of interest to Genentech, Affimed said. Genentech will be responsible for clinical development and commercialization worldwide.

  • GlobeNewswire24 days ago

    Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

    Affimed N.V. (AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK and T cells), today announced that it has entered into a strategic collaboration agreement with Genentech, a member of the Roche Group, to develop and commercialize novel NK cell engager-based immunotherapeutics to treat multiple cancers. Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech.

  • Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates
    Zackslast month

    Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates

    Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 5.88% and -70.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

    Heidelberg, Germany, August 8, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate ...

  • ACCESSWIRElast month

    Affimed N.V. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To listen ...

  • GlobeNewswire2 months ago

    Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

    Heidelberg, Germany, August 3, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on August ...

  • ACCESSWIRE2 months ago

    Free Technical Research on Advaxis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.

  • Implied Volatility Surging for Affimed (AFMD) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Affimed (AFMD) Stock Options

    Affimed (AFMD) needs investors to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire3 months ago

    MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens

    MolMed S.p.A. (MLMD.MI), a medical biotechnology company focusing on research, development, manufacturing, and clinical validation of cell & gene therapies to treat cancer and rare diseases and AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, today announced that they have entered into a three-year Master Agreement aimed at providing MolMed with selected and optimized antibodies for the development of new Chimeric Antigen Receptors (CARs), targeting both liquid and solid tumors. Under the agreement, AbCheck will use its proprietary discovery platform to select, optimize and deliver multiple human single-chain variable fragments (scFvs), specifically recognizing each MolMed target candidate.

  • Benzinga3 months ago

    Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data

    Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...